Single-dose quinidine treatment inhibits mexiletine oxidation in extensive metabolizers of debrisoquine
- 31 December 1991
- journal article
- other
- Published by Elsevier BV in Life Sciences
- Vol. 48 (26), PL123-PL128
- https://doi.org/10.1016/0024-3205(91)90618-l
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Inhibitory studies of mexiletine and dextromethorphan oxidation in human liver microsomesBiochemical Pharmacology, 1990
- RELATIONSHIP BETWEEN PLASMA MEXILETINE LEVELS AT STEADY‐STATE: PRESENCE OF VENTRICULAR ARRHYTHMIAS AND SIDE EFFECTSFundamental & Clinical Pharmacology, 1987
- Quinidine and the identification of drugs whose elimination is impaired in subjects classified as poor metabolizers of debrisoquine.British Journal of Clinical Pharmacology, 1986
- Quinidine: potent inhibition of sparteine and debrisoquine oxidation in vivo.British Journal of Clinical Pharmacology, 1986
- Sparteine oxidation is practically abolished in quinidine-treated patients.British Journal of Clinical Pharmacology, 1986
- Pharmacology, electrophysiology, and pharmacokinetics of mexiletineAmerican Heart Journal, 1984
- Competitive inhibition of sparteine oxidation in human liver by β-adrenoceptor antagonists and other cardiovascular drugsLife Sciences, 1984
- Mexiletine in the treatment of resistant ventricular arrhythmias: enhancement of efficacy and reduction of dose-related side effects by combination with quinidine.Circulation, 1983
- A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population.Journal of Medical Genetics, 1980
- Determination of debrisoquine and its 4-hydroxy metabolite in biological fluids by gas chromatography with flame-ionization and nitrogen-selective detectionJournal of Chromatography A, 1977